248 related articles for article (PubMed ID: 23565736)
1. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
Shi J; Zhou Z; Di W; Li N
BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
[TBL] [Abstract][Full Text] [Related]
2. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
3. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
Liu YJ; Yan PS; Li J; Jia JF
World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
[TBL] [Abstract][Full Text] [Related]
4. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.
Zhang J; Chang B; Liu J
Hum Pathol; 2013 Sep; 44(9):1882-9. PubMed ID: 23664487
[TBL] [Abstract][Full Text] [Related]
5. CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer.
Motohara T; Fujimoto K; Tayama S; Narantuya D; Sakaguchi I; Tashiro H; Katabuchi H
Obstet Gynecol; 2016 Jun; 127(6):1003-1011. PubMed ID: 27159753
[TBL] [Abstract][Full Text] [Related]
6. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
7. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.
Li Z; Chen K; Jiang P; Zhang X; Li X; Li Z
Diagn Pathol; 2014 Apr; 9():79. PubMed ID: 24708709
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
[TBL] [Abstract][Full Text] [Related]
9. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.
Li L; Hao X; Qin J; Tang W; He F; Smith A; Zhang M; Simeone DM; Qiao XT; Chen ZN; Lawrence TS; Xu L
Gastroenterology; 2014 Apr; 146(4):1108-18. PubMed ID: 24397969
[TBL] [Abstract][Full Text] [Related]
10. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma.
Gansauge F; Gansauge S; Rau B; Scheiblich A; Poch B; Schoenberg MH; Beger HG
Cancer; 1997 Nov; 80(9):1733-9. PubMed ID: 9351541
[TBL] [Abstract][Full Text] [Related]
11. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of CD44 variants expression in colorectal cancer.
Li XD; Ji M; Wu J; Jiang JT; Wu CP
Tumori; 2013; 99(1):88-92. PubMed ID: 23549006
[TBL] [Abstract][Full Text] [Related]
14. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
Afify A; Purnell P; Nguyen L
Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
[TBL] [Abstract][Full Text] [Related]
15. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation.
Yanagisawa N; Mikami T; Mitomi H; Saegusa M; Koike M; Okayasu I
Cancer; 2001 Jan; 91(2):408-16. PubMed ID: 11180088
[TBL] [Abstract][Full Text] [Related]
16. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases.
Concin N; Hefler L; van Bavel J; Mueller-Holzner E; Zeimet A; Daxenbichler G; Speiser P; Hacker N; Marth C
Gynecol Oncol; 2003 Apr; 89(1):9-15. PubMed ID: 12694648
[TBL] [Abstract][Full Text] [Related]
17. Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9.
Gupta A; Cao W; Sadashivaiah K; Chen W; Schneider A; Chellaiah MA
ScientificWorldJournal; 2013; 2013():493689. PubMed ID: 23476138
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors.
Afify AM; Tate S; Durbin-Johnson B; Rocke DM; Konia T
Int J Biol Markers; 2011; 26(1):50-7. PubMed ID: 21279958
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.
Afify AM; Ferguson AW; Davila RM; Werness BA
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):309-14. PubMed ID: 11759056
[TBL] [Abstract][Full Text] [Related]
20. Promotion of ovarian cancer cell invasion, migration and colony formation by the miR‑21/Wnt/CD44v6 pathway.
Wang Y; Yang X; Yuan M; Xian S; Zhang L; Yang D; Cheng Y
Oncol Rep; 2019 Jul; 42(1):91-102. PubMed ID: 31115569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
